A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
Ronan P McLaughlinJichao HeVera E van der NoordJevin RedelJohn A FoekensJohn W M MartensMarcel SmidYinghui ZhangBob van de WaterPublished in: Breast cancer research : BCR (2019)
Our results highlight that dual inhibition of cdc7 and CDK9 by PHA-767491 is a potential strategy for targeting TNBC resistant to EGFR-TKIs.